



Press release from Emotra AB (publ)  
Göteborg, January 23, 2014

## Emotra signs co-operation agreement with the University of Rome

**Emotra has signed a co-operation agreement with a psychiatric clinic at the Saint Andrea Hospital of the University of Rome. This is the fifth clinic to sign an agreement to participate in Emotra's clinical multi-centre study for the purpose of evaluating the use of EDOR to assess potential suicide risks.**

*"The psychiatric clinic at the Saint Andrea Hospital is the second Italian clinic to sign an agreement regarding co-operation in our multi-centre study. On January 17 we signed an agreement with the University of Genoa, and today another one with the University of Rome. Discussions are also ongoing with other clinics in Italy, and hopefully these will shortly be participating in our collaborative trials of the EDOR method," states Claes Holmberg, CEO of Emotra AB.*

So far, five clinics have signed co-operation agreements with Emotra. The Company aims to involve around 15 European clinics in the clinical trials of Emotra's testing method for an initial market introduction in the first quarter 2014. We expect these trials to continue over the next two years, and discussions and negotiations are ongoing with several clinics from different countries. For the purpose of preparing these clinical trials, applications to ethical committees as well as for CE certification are simultaneously being drafted.

At present, Emotra is in the middle of a very dynamic phase, and its activities involve an increasing number of clinical centres. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When international, scientific support for EDOR from these clinics has grown sufficiently strong, we will launch the method in Europe.

**For further information, please contact:**

*Claes Holmberg, CEO*

*Telephone: +46 708 25 45 47*

*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

*Lars-Håkan Thorell, Head of Research*

*Telephone: +46 733 95 31 20*

*E-mail: [lars@emotra.se](mailto:lars@emotra.se)*

---

**Emotra AB** is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. *Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*